debrisoquin and 4-hydroxypropranolol

debrisoquin has been researched along with 4-hydroxypropranolol in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (80.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Biollaz, J; Koshakji, RP; Shaheen, O; Wilkinson, GR; Wood, AJ	1
Freestone, S; Jackson, PR; Lennard, MS; Ramsay, LE; Tucker, GT; Woods, HF	2
Koshakji, RP; Raghuram, TC; Wilkinson, GR; Wood, AJ	1
Chadwick, IG; Ellis, SW; Haq, I; Jackson, PR; Lennard, MS; Ramsay, LE; Rowland, K; Tucker, GT; Yeo, WW	1

Trials

1 trial(s) available for debrisoquin and 4-hydroxypropranolol

Article	Year
Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. British journal of clinical pharmacology, 1994, Volume: 38, Issue:1 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Metoprolol; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Phenotype; Propranolol; Recombinant Proteins; Saccharomyces cerevisiae	1994

Article

Year

Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.

British journal of clinical pharmacology, 1994, Volume: 38, Issue:1

Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Metoprolol; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Phenotype; Propranolol; Recombinant Proteins; Saccharomyces cerevisiae

1994

Other Studies

4 other study(ies) available for debrisoquin and 4-hydroxypropranolol

Article	Year
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Clinical pharmacology and therapeutics, 1989, Volume: 45, Issue:4 Topics: Adult; Debrisoquin; Enzyme Induction; Glucuronates; Humans; Isoquinolines; Male; Metabolic Clearance Rate; Mixed Function Oxygenases; Phenotype; Propranolol	1989
The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype. British journal of clinical pharmacology, 1984, Volume: 17 Suppl 1 Topics: Adrenergic beta-Antagonists; Debrisoquin; Humans; Hydroxylation; Isoquinolines; Kinetics; Male; Oxidation-Reduction; Phenotype; Propranolol	1984
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clinical pharmacology and therapeutics, 1984, Volume: 36, Issue:1 Topics: Adult; Chromatography, High Pressure Liquid; Debrisoquin; Heart Rate; Humans; Hydroxylation; Male; Phenotype; Physical Exertion; Polymorphism, Genetic; Propranolol	1984
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. British journal of clinical pharmacology, 1984, Volume: 17, Issue:6 Topics: Adult; Debrisoquin; Humans; Isoquinolines; Kinetics; Male; Oxidation-Reduction; Phenotype; Propranolol	1984